Characteristics included proportion of individuals in a fasting state when screened, proportion of individuals with known diabetes among those screened, proportion of positive screenees returning for confirmatory diagnosis, and proportion of confirmatory testing done at public vs. private providers.
This was measured as the proportion of patients screened, proportion of patients at nutritional risk with a nutritional plan, that is, who were either under treatment or for whom treatment was planned, and the proportion of patients seen by a dietician.
Screening proportions show the effect of the breast screening age range.
In prevalence screening the proportion of screen detected cancers diagnosed at stage I (Dukes' A) was 46.5%, but this fell to 41% for first incidence screening and to 35% for second incidence screening.
The rate of subjects reporting having been screened (either individually or through screening programs), the rate of GPs systematically recommending CRC screening, the proportion of subjects screened undergoing FOBT, compared to endoscopy, as well as that of subjects having performed a test within the last two years, were all increased in departments where an organised screening program exists.
A publication was considered for inclusion if it reported on the evaluation of an intervention to increase chlamydia screening rates in a primary care clinic, through a comparison with chlamydia screening rates (proportion of patients screened within a given time period) in a control group or control time period.
We assessed 3-year screening proportions by categories of BMI, age, sex, race/ethnicity, and baseline hypertension and (except for blood glucose screening) diabetes mellitus status.
Screening coverage (proportion of the woman population for which screening is available) and participation (women regularly attending screening) have gradually increased in all areas, included in this study.
These include the preparedness of GPs to engage in opportunistic screening, the proportion of eligible individuals who are willing to choose lifelong medication and their compliance with treatment.
Poisson regression models were built to examine the strength of the association between rates of mortality and categories of screening coverage, proportion of women looking for treatment, and proportion of women who do not collect results.
